Analysts Set Repligen Co. (NASDAQ:RGEN) PT at $189.57

Shares of Repligen Co. (NASDAQ:RGEN) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $189.57.

Several research firms recently commented on RGEN. UBS Group cut their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Guggenheim started coverage on shares of Repligen in a research report on Tuesday, June 18th. They set a “neutral” rating for the company. Royal Bank of Canada reissued an “outperform” rating and set a $190.00 price target on shares of Repligen in a report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st.

Repligen Stock Up 1.8 %

RGEN opened at $152.95 on Thursday. Repligen has a fifty-two week low of $110.45 and a fifty-two week high of $211.13. The company has a market capitalization of $8.57 billion, a P/E ratio of 611.82, a P/E/G ratio of 5.27 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. The firm’s fifty day moving average price is $137.80 and its two-hundred day moving average price is $163.60.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same period in the previous year, the business earned $0.53 EPS. The firm’s revenue was down 3.2% on a year-over-year basis. On average, analysts anticipate that Repligen will post 1.45 EPS for the current year.

Insider Buying and Selling at Repligen

In other news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Repligen news, CEO Anthony Hunt purchased 2,000 shares of the stock in a transaction dated Friday, June 14th. The stock was bought at an average price of $124.08 per share, for a total transaction of $248,160.00. Following the transaction, the chief executive officer now directly owns 165,177 shares in the company, valued at $20,495,162.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares in the company, valued at $3,190,969.87. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

A number of institutional investors have recently bought and sold shares of the business. YHB Investment Advisors Inc. acquired a new stake in shares of Repligen during the first quarter worth $26,000. Andra AP fonden bought a new stake in shares of Repligen in the 2nd quarter valued at about $25,000. Lazard Asset Management LLC raised its position in shares of Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 136 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in shares of Repligen by 152.1% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 146 shares during the period. Finally, International Assets Investment Management LLC bought a new position in Repligen during the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.